When temperatures rise, so do the risks of hazardous heat exposure in the workplace. OSHA’s Pamela Barclay discusses what employers can do to safeguard workers in their warehouses and DCs.
David Maloney has been a journalist for more than 35 years and is currently the group editorial director for DC Velocity and Supply Chain Quarterly magazines. In this role, he is responsible for the editorial content of both brands of Agile Business Media. Dave joined DC Velocity in April of 2004. Prior to that, he was a senior editor for Modern Materials Handling magazine. Dave also has extensive experience as a broadcast journalist. Before writing for supply chain publications, he was a journalist, television producer and director in Pittsburgh. Dave combines a background of reporting on logistics with his video production experience to bring new opportunities to DC Velocity readers, including web videos highlighting top distribution and logistics facilities, webcasts and other cross-media projects. He continues to live and work in the Pittsburgh area.
As the calendar turns to June and temperatures across North America start to climb, millions of U.S. workers face increasing risk of heat stress in the workplace. Warehouses, distribution centers, manufacturing plants, and transload facilities often lack good climate control. In buildings without air conditioning, temperatures can easily top 100 degrees with high humidity—conditions that raise the risk of heat stroke and heat fatigue for those working inside. In addition to the safety risks, heat exposure has economic implications: Overall productivity can suffer when workers are stressed by high temperatures.
To learn more about how rising temperatures can affect the health and productivity of workers, we turned to Pamela Barclay, a health scientist with the Directorate of Standards and Guidance at OSHA. She focuses on safety and health programs at the agency and coordinates the Safe + Sound and Heat Illness Prevention campaigns.
Barclay graduated from the University of Michigan with a Master of Public Health degree in environmental health and risk analysis, and a Master of Science degree in behavior, education, and communication.
Q: Why are summer months more dangerous for workers in industrial settings?
A: It does not have to be extremely hot for a worker to develop heat illness. Performing physical labor in a warm environment can be enough to trigger heat illness. Heat exposure can happen indoors (in manufacturing plants, restaurants, bakeries, etc.) or outdoors (in agriculture, construction, and the like) and can occur during any season if the conditions are right, not only during heat waves.
A number of factors can contribute to heat stress in workers. They include high temperature and high relative humidity, which makes it difficult for the body to cool itself through sweating; radiant heat from sunlight; artificial heat sources such as furnaces; and poor air circulation. Some job-related risk factors include strenuous physical activity and heavy or non-breathable work clothes that reduce the body’s ability to dissipate excess heat.
Q: Why is it important to pay special attention to new and returning workers?
A: Research suggests that almost half of heat-related deaths occur on the worker’s first day on the job. While heat exposure can put any worker at risk, it’s important for employers to acclimatize new and returning workers to allow them to adjust to working in the heat. This can be done by gradually increasing workloads and allowing workers to take more frequent breaks during the first week as they build their tolerance.
Q: What are some of the signs that a person is being affected by heat stress?
A: Employers and workers should become familiar with the symptoms of heat illness. These symptoms include (but are not limited to) headaches, nausea, heavy sweating, hot dry skin, elevated body temperature, thirst, and decreased urine output. It’s especially critical that they be trained to recognize symptoms that indicate a medical emergency. These include abnormal thinking or behavior, slurred speech, seizures, and loss of consciousness.
Do not try to diagnose what type of heat illness is occurring (heat exhaustion, heat stroke, etc.). Diagnosing types of heat illness is often difficult because symptoms of multiple heat-related illnesses can occur together. Time is of the essence. These conditions can worsen quickly and result in fatalities. Cool the worker and call 911.
Q: You mention cooling the worker. What actions should be taken if heat illness is suspected?
A: When heat illness symptoms are present, employers and co-workers should promptly provide first aid. This includes actions like taking the worker to a cooler area, either with A/C or in the shade; immersing the worker in cold water or an ice bath; removing outer layers of clothing, especially heavy protective clothing; placing ice or cold wet towels on the head, neck, trunk, armpits, and groin; and using fans to circulate air around the worker.
Workers showing any signs of heat illness should never be left alone. When in doubt, call 911.
Q: What should employers do to mitigate the risk of heat stress within their facilities?
A: Under the OSH Act [the Occupational Safety and Health Act of 1970—the law that created OSHA], employers are responsible for protecting workers from known hazards, including heat. To mitigate the risk of hazardous heat, employers should plan ahead.
At a minimum, employers should have protocols in place to ensure the availability of water, rest breaks, and shade. This means providing cool drinking water, scheduling rest breaks, and providing a shaded or cool area for workers to recover from the heat when they take those breaks.
Q: You mentioned planning ahead. What should this entail?
A: Establishing a heat injury and illness prevention plan is vital to keeping workers safe. When developing a plan, there are various elements that employers should consider. These include determining who will provide insight on a daily basis, identifying steps [for acclimating] new and returning workers so they will gradually develop heat tolerance, and [developing strategies for protecting] people at the worksite who may be at increased risk.
Employers should also ensure that their protocols for responding to heat illness are effective. This should include implementing the appropriate controls to reduce heat exposure, outlining how to respond to a heat advisory or heat warning in the area, and having daily on-site monitoring of environmental conditions and signs of heat illness regardless of job shift.
Workers should also be trained to recognize the risks and signs of heat illness. This training is key to prevention and should underscore the importance of water, rest, shade, and first aid for heat illness.
Q: What can workers themselves do to minimize their risk of developing heat illness?
A: Heat illnesses can affect anyone, regardless of age or physical condition. However, some workers may handle heat stress less effectively than others. There are many factors that have a role in creating a heat-stress risk to workers. These include health conditions like heart disease, high blood pressure, obesity, and diabetes. They also include physical characteristics, such as age, level of physical fitness, pregnancy, and how acclimatized an individual is to the heat.
In addition, some medications, like diuretics, may make workers more susceptible to heat illness. Furthermore, certain health behaviors such as low water intake and the use of alcohol or illicit drugs—like opioids, methamphetamine, and cocaine—are risk factors for heat illness. When in doubt, workers should talk to their health-care provider about whether they can work safely in the heat.
Employers should recognize that not all workers tolerate heat the same way. When heat hazards are present, workers should receive training from their employers about personal factors that can make them more susceptible to heat-related illness, and employers should enact workplace controls that focus on making jobs safe for all of their workers.
Q: Are there OSHA regulations that cover workplace heat stress that companies should be aware of?
A: Under the OSH Act, employers are responsible for providing workplaces free of known safety and health hazards. In October 2021, OSHA published an Advance Notice of Proposed Rulemaking (ANPRM) for Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings. The ANPRM announced that OSHA is initiating the rulemaking process to consider a heat-specific workplace standard.
The next step in the rulemaking process will be to convene a Small Business Advocacy Review Panel, in accordance with the requirements of the Small Business Regulatory Enforcement Fairness Act (SBREFA), to hear comments from small-entity representatives on the impacts of any heat-specific standard. Updates on the rulemaking process will be provided on OSHA’s heat rulemaking web page.
Some states have also promulgated their own standards covering heat stress. Currently, these states are California, Colorado, Minnesota, Oregon, and Washington. These regulations vary, so we encourage employers in these states to review their state’s regulation and reach out to their state or OSHA Region to ensure they are meeting the requirements for their respective standard.
Q: What are the penalties for failure to comply with OSHA regulations for assuring a safe work environment?
Q: How can employers stay up to date on OSHA’s occupational heat hazard-related efforts?
A: Check out OSHA’s Heat Illness Prevention Campaign for resources that can help! Sign up for the monthly e-newsletter, “The Heat Source,” to stay up to date on new materials and ways to prevent heat illness at work. Your readers can find this information and more on OSHA’s website.
Our newest opportunity for stakeholders to engage is by participating in OSHA’s “Beat the Heat” contest, which is designed to raise awareness about the hazards of heat exposure in indoor and outdoor workplaces. The contest is open to stakeholders (businesses, unions, educational institutions, government entities, and individuals) nationwide. Participants must create an awareness tool, such as an infographic, training curriculum, poster, or logo, for workplaces to increase heat hazard recognition among employers and workers. The contest is open now! To learn more about the competition, visit the OSHA website. The deadline for entries is June 9.
Its latest expansion adds both specialized U.S./Mexico cross-border and international trade compliance services. "JAMCO's capabilities align perfectly with our growth strategy and commitment to providing comprehensive, highly specialized premium logistics solutions,” Imperative CEO Dante Fornari said in a release. “JAMCO will significantly enhance our service offering by adding highly differentiated and integrated cross-border trade and logistics services. We'll be better positioned to support existing customers who manufacture in Mexico while providing JAMCO clients with our expedited mission-critical shipping and global forwarding capabilities."
According to Imperative, that move is significant because Laredo, Texas-based JAMCO is well located to serve the growing nearshoring trend that saw Mexico become the largest trading partner of the United States in 2023, surpassing China with over $800 billion in trade value. Amid that growth, Laredo, Texas, has also solidified its role as the top U.S. port, measured by trade value, representing approximately 40% of all U.S.-Mexico trade flows.
Seagull Software, which makes “BarTender” label management software, today said it has combined with Mojix, a provider of item-level inventory management and traceability.
As a single company, the combined firms will offer new capabilities in end-to-end supply chain management, leveraging BarTender’s global customer base and value-added channel partner network with more than 250,000 customers across 175 countries.
“We believe that labeling is the key to addressing the traceability challenge,” Dan Doles, now acting CEO and Director of Seagull, said in a release. “BarTender’s labeling software is ubiquitous at the front end of the supply chain, enabling the printing of more than 100 billion labels each year. By combining with Mojix, we will capture and track that data through the supply chain, providing unparalleled item-level traceability and visibility.”
That approach will allow the partners to provide their customers with value-added solutions for compliance, sustainability, serialization, and inventory and asset management requirements across the supply chain ecosystem, according to Chris Cassidy, the newly appointed Chief Revenue Officer of Seagull.
The features are based on SAP’s “generative AI copilot” platform called Joule, launched about a year ago. The latest upgrades to that product add collaborative AI agents that truly speak the language of business, expand Joule’s capabilities to support 80% of SAP’s most-used business tasks, and embed Joule more deeply within the company’s portfolio.
Specifically, collaborative multi-agent systems can now deploy specialized AI agents to tackle specific tasks and enable them to collaborate on intricate business workflows, adapting their strategies to meet shared objectives. SAP is infusing Joule with multiple collaborative AI agents that will combine their unique expertise across business functions to collaboratively accomplish complex workflows. These AI agents enhance productivity by breaking down silos and freeing workers to concentrate on areas where human ingenuity thrives.
And Walldorf, Germany-based SAP also said it had met its goal to train workers how to use those powerful new AI tools by upskilling 2 million people worldwide by 2025. That approach has lowered the world’s digital skills gap through role-based certifications, free training materials, and hands-on opportunities for developers. To continue that program, SAP says it will continue to expand its portfolio of AI-related learning opportunities, including courses on generative AI, AI ethics, and the company’s advanced AI tools and platforms.
For players in the drug distribution business, the countdown is on. In less than two months, every business involved in the pharmaceutical supply chain must be fully compliant with the Drug Supply Chain Security Act (DSCSA)—a 2013 law containing strict traceability requirements for the distribution of certain prescription drugs. Over the past decade, the DSCSA has been implemented in phases, but now the clock is running out. The law takes full effect on Nov. 27, barring any further adjustments or delays.
Among other measures, the DSCSA requires drug manufacturers to affix a unique product identifier, essentially a barcode, to every package so it can be tracked and traced during its journey through the supply chain. To thwart drug counterfeiters, the new law further requires wholesalers and drug dispensers to verify the validity of products they handle to assure they are genuine.
Is the pharmaceutical industry ready for all this? To find out, we spoke with Elizabeth Gallenagh, general counsel and senior vice president, supply chain integrity at the Healthcare Distribution Alliance(HDA), a national organization that represents U.S. health-care distributors. In addition to serving as HDA’s chief legal officer, Gallenagh is also the group’s primary expert on prescription drug traceability, supply chain safety and integrity, distributor licensure, and tax issues. She is a graduate of the George Mason University School of Law and George Washington University.
Gallenagh recently spoke with David Maloney, **{DC Velocity’}s group editorial director, about the enactment of DSCSA for an episode of the “Logistics Matters” podcast.
Q: First of all, can you tell us a little bit about the Healthcare Distribution Alliance?
A: Yes, the Healthcare Distribution Alliance, or HDA, is a national trade organization representing pharmaceutical distributors, also known as wholesalers. We have about 40 members that purchase drugs from manufacturers. They store the products in their warehouses and then fill orders for pharmacy customers throughout the country.
Q: The Drug Supply Chain Security Act will go into final effect in November. What’s the intent of the legislation?
A: The Drug Supply Chain Security Act—or as we call it, the DSCSA—is a law that was enacted in 2013. Its intent was to put together a national framework for drug supply chain security, essentially to enable a tighter, safer, more secure supply chain for the domestic U.S. market.
It involves all trading partners and ultimately will create an interoperable system that enables investigations by tracing a product with every transaction or sale of that product throughout the supply chain, down to the provider level.
Q: What are the law’s major requirements?
A: The law was actually phased in over a period of about 10 years. Many of the major requirements went into effect throughout that initial 10-year period—things like requirements mandating that manufacturers serialize their products and stipulating that trading partners only do business with other authorized trading partners. Authorized trading partners are defined as those that are duly licensed or registered with the Food and Drug Administration (FDA) or licensed by the states.
It also requires tracking of product with every transaction. A transaction is defined as a sale of the product, essentially from one authorized trading partner to another. And as we progress into the final phase, the law will also require serialized data, basically transaction information at the serial-number level that moves with the product through every transaction throughout the supply chain.
Q: You’ve said that the industry has had years to ramp up to comply with the law. Are our pharmaceutical supply chains ready for the final phase?
A: I think that’s still the $64,000 question. I can speak for our members, who have been doing everything in their power to get their own systems and processes ready to receive the serialized products and data, and then to transmit that serialized data with the product to their pharmacy customers.
That said, there are still some gaps in the system. We have been in a “stabilization” period that expires on Nov. 27. During this period, everybody has been testing and bringing product and data transactions live into production. I will tell you that many are ready, but there are still bugs that are being worked out as we race toward November.
I should also note that on Aug. 19, the HDA sent a letter to the FDA stating that “despite a concerted effort, some in the supply chain appear to remain short of reaching our joint goal of complete implementation.” In its letter, the group urged the FDA to “take immediate action to forestall potential disruptions to the drug supply chain and patient care that could stem from incomplete implementation of the enhanced drug distribution security (EDDS) requirements” and asked the agency to adopt “a phased, stepwise approach” to implementing the requirements in order to avoid disruptions to the movement of drugs through the supply chain.
Q: Will penalties be imposed on companies that fail to meet the deadline?
A: There will be penalties. But it’s important to note that the DSCSA is really about setting up the framework for tracking and tracing products—so that a manufacturer will only be permitted to sell its product downstream if it is a serialized product and the manufacturer can transmit the corresponding serialized data with the product. And then a distributor can only receive that product and purchase it if it has the corresponding data.
Q: Of course, this is only possible if you have the right technology in place to monitor and track drugs as they move through the supply chain. What kind of technologies are being deployed to make this possible?
A: The key to all of this is the barcode, which is mandated under the law in terms of the way that product is serialized. Everybody in the supply chain has to have the capability to utilize the barcode. If you’re a manufacturer, you have to incorporate that 2-D barcode with the serialized data into that product’s label. And that should already be in place under the first phases of the law.
Downstream partners will have to be able to read that barcode and import that data into their systems. This also enables verification of the product at the unit level.
In addition, we’re also deploying what we call EPCIS [a global data-sharing standard developed by the global standards organization GS1 that allows businesses to capture and share information about the movement and status of goods]. That is the backbone for getting all of this serialized data flowing to all of the requisite trading partners throughout the supply chain.
Q: As we learned during the push to distribute Covid-19 vaccines, a good number of pharmaceutical products must be temperature- or humidity-controlled. Will these new regulations help ensure that they’re properly handled as they move through the supply chain?
A: The DSCSA doesn’t speak specifically to temperature controls. However, there are other parts of the law [the overall Drug Quality and Security Act, which includes the DSCSA as well as the Compounding Quality Act] that do require those controls to be in place. That said, the DSCSA does require affected parties to do business with authorized trading partners. And in order to be an authorized trading partner, you have to adhere to temperature controls and safety rules for products, product handling, etc.
Q: Many of our pharmaceuticals are manufactured overseas, in China and India, for example. Do foreign manufacturers have to comply with DSCSA requirements?
A: If a foreign entity is producing product for use in the U.S. domestic market, the product has to be approved by the FDA. And it also has to meet DSCSA requirements.
Q: We hear a lot about counterfeit products infiltrating the drug supply chain. Will these new regulations reduce the number of counterfeits in the market?
A: We certainly hope so. All of this really started [as an effort to combat the rise in] counterfeit products and transactions back in the early 2000s. Obviously, the idea is to deter counterfeiters from infiltrating the U.S. drug supply chain. But really, what the law does is provide tools for the FDA and regulatory agencies to investigate suspect and illegitimate product, as well as tools that will enable the trading partners that are involved in the transactions to identify suspect product, flag it, quarantine it, investigate it, and deem it OK or deem it illegitimate based on their investigations.
So it really gives some investigatory and prosecutorial tools to the agencies. And it puts a process in place with the technology and serialization to pinpoint whether something is good product through verification with the manufacturer or through tracing of the product data that has accompanied the product throughout its journey through the supply chain.
Q: Drug prices in the U.S. are notoriously high compared with prices in many other countries. Will these new requirements add to the overall cost of supplying medication?
A: I haven’t seen any data that alludes to DSCSA compliance adding to drug costs. It’s an industry that’s built around efficiency, and so my sense is that [pharma industry players] probably have also built in plans over the last decade to absorb some of those costs. That said, the law also established a national tracking and tracing framework, where before we had a 50-state patchwork of regulations. So there would likely be some efficiencies gained from following a single, nationwide protocol, even though it’s a huge undertaking, versus doing it 50 different ways across the country.
Q: Now that DSCSA is nearing full implementation, how are your members feeling about the process?
A: Our members have been committed to this from the very beginning. We were very involved in negotiating on the legislation and pushing these concepts. We really have been working toward implementation from the get-go and throughout this entire 11-year period; we very much want to get to full implementation. But in the beginning, there may be some hiccups. We may hit a few bumps along the way.
A colleague of mine used to say, “We don’t know what we don’t know.” And I think that at each phase as we deploy new technologies and new processes, we will learn new ways to do things more efficiently. So we’re pushing hard toward November, and we are very hopeful.
Autonomous inventory management system provider Corvus Robotics is delivering drone technology for lights-out warehouse environments with the newest version of its Corvus One drone system, announced today.
The update is supported by an $18 million funding round led by S2G Ventures and Spero Adventures.
“Corvus Robotics fits our mission to invest in companies that truly transform the way business is conducted,” Marc Tarpenning, co-founder of Tesla and partner at Spero Ventures, said in a press release Tuesday. “Other than a landing pad, its drone-powered system requires no infrastructure, is quick and easy to deploy, and cost-effective to manage. It literally merges with the existing warehouse environment.”
Corvus Robotics’ drone-based inventory management system uses computer vision and generative AI to understand its environment, flying autonomously in both very narrow aisles—a minimum width of 50 inches—and in very wide aisles. It uses obstacle detection to operate safely in warehouses and features an advanced barcode scanning system that can read any barcode symbology in any orientation placed anywhere on the front of cartons or pallets, according to the company.
The lights-out feature is already in use at customer locations.
“Being able to run inventory checks 24/7 without operator assistance has been a game changer,” Austin Feagins, senior director of solutions at third-party logistics services (3PL) provider Staci Americas, said in the release. “The lights-out capability in the Corvus One system allows our inventory teams to correct discrepancies off-shift and pre-shift before production starts each day, limiting fulfillment delays and production impacts.”